Review Article
The Role of Gender in Juvenile Idiopathic Arthritis-Associated Uveitis
Table 2
Summary of ocular complications during followup in some of the noted studies.
| | |
Heiligenhaus et al.
2005 [11] | Edelsten et al.
2003 [12] | Saurenmann
et al.
2007 [14] | Gregory et al.
2013 [19] | Woreta et al.
2007 [20] | Thorne et al.
2007 [24] | Edelsten et al.
2002 [21] | Ayuso et al.
2010 [25] | Sabri et al.
2008 [26] |
| | Mean ± SD/median age at the time of diagnosis of uveitis | 5.2 ± 3.2 Y | N/R | 8.3 Y | 4.1 (4 m–16.9) Y | 7 (1–36) Y | 7 (1–36) Y | 50 (4–149) m | M: 4.3 (1.7–13.8) Y
F: 4.2 (1.7–16) Y | N/R | Follow-up time for uveitis,
Mean ± SD/median (range) | 5.6 ± 4.9 Y | N/R | 6.3 (0–23.2) Y | 2.62 (0–24) Y | | 3 (1 m–15) Y | 4 Y | M: 11(1.1–27.5) Y
F: 7.2(1.1–22.9) Y | 6.3 (0.1–23.2) Y | | Type of uveitis | | | | | | | | | | | Anterior | N/R | 70% | 96.5% | N/R | 86.7% | 86.7% | N/R | 99% | 96.5% | | Acute anterior | N/R | 16% | 16.2% | N/R | N/R | N/R | N/R | N/R | 16.2% | | Chronic anterior | N/R | 54% | 68.3% | N/R | N/R | N/R | N/R | N/R | 68.3% | | Anterior recurrent uveitis | N/R | 0 | 12% | N/R | N/R | N/R | N/R | N/R | 12% | | Intermediate | N/R | 0 | 0 | N/R | 13.3% | 13.3 | N/R | 0 | 0 | | Posterior | N/R | 30% | 0 | N/R | 0 | 0 | N/R | 0 | 0 | | Panuveitis | N/R | N/R | 3.5% | N/R | 0 | 0 | N/R | 1% | 3.5% | | Structural ocular complications | | | | | | | | | | | At least one OC at presentation | 45% | N/R | N/R | 60.2% | 67% | 67% | N/R | N/R | N/R | | At least one OC after F/U | 56% | N/R | 37.3% | N/R | N/R | 0.33 EY | 21% | N/R | 32.5% | | Band keratopathy | 29% | N/R | 14.1% | 32.1% (126/393)* | 31.5%¥ | 0.08/EY | N/R | 16% | 12.3% | | Posterior synechiae | 27% | N/R | 21.8% | 22.9% (97/423)* | 27.5 %¥ | | N/R | 40% | 17.1% | | Cataract | 26% | N/R | 23.2% | N/R | 22.5%¥ | 0.04/EY | 21% | 42% | 20.2% | | Glaucoma | 8% | N/R | 15.5% | N/R | | 0.05/EY | 14% | 25% | | | Ocular hypertension ≥ 21 mm Hg | N/R | N/R | N/R | 24.6 % (125/508)* | 15.3%¥ | 0.18/EY | N/R | N/R | 13.6% | | Ocular hypertension ≥ 30 mm Hg | N/R | N/R | N/R | 10.6% (61/577)* | | | N/R | N/R | | | Hypotony | N/R | N/R | N/R | 10.5% (60/569)* | 9.3%¥ | 0.09/EY | N/R | N/R | N/R | | Cystoid macular edema | 6% | N/R | 4.9% | 8.9% (50/564)* | 3%¥ | 0.04/EY | N/R | 19% | 3.9% | | Epiretinal membrane | N/R | N/R | | 8.1% (46/567)* | 3.8%¥ | 0.06/EY | N/R | N/R | N/R | | Final VA < 20/50 (visual impairment) | 31% | N/R | 3.4% | 36.8% (131/356)* | 36.4% | 0.10/EY | 11% | N/R | 3.4% | | Final VA < 20/200 (Blindness) | 12% | 17% | 5.7% | 21% (95/452)* | 23.7% | 0.08/EY | 6% | N/R | 5.7% |
|
|
EY: eye-year; F: female; F/U: followup; IR: incidence rate; M: male; m: months; N: number; N/R: result not reported; OC: ocular complications; VA: visual acuity; Y: years.
*Incidence; ¥prevalence at presentation.
|
